FOLH1 and glioblastoma: Recently [68Ga]-PSMA–Glu–NH–CO–NH–Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-11) has also been shown to be a promising positron emission tomography (PET) imaging agent for the diagnosis of patients with primary GBM [7] and for treatment response assessment [8,9] and, as such, it has great potential as an imaging biomarker for management of GBM patients [7].